CMD Intelligence helps long-duration capital understand which biomedical advances are real, which will translate, and what they could change across health systems, insurance and demographic risk. We combine scientific expertise with ecosystem intelligence to distinguish scientific novelty from durable consequence; making emerging scientific and institutional trajectories legible enough for better judgement.
We produce structured intelligence that give allocators a clear, defensible view of where frontier science is heading and where the capital opportunity actually sits. Our research is built from direct relationships with leading labs, founders, and clinicians doing the work, and we structure our work for the way institutional investment committees actually make decisions.
We produce structured intelligence that give allocators a clear, defensible view of where frontier science is heading and where the capital opportunity actually sits. Our research is built from direct relationships with leading labs, founders, and clinicians doing the work, and we structure our work for the way institutional investment committees actually make decisions.
We produce structured intelligence that give allocators a clear, defensible view of where frontier science is heading and where the capital opportunity actually sits. Our research is built from direct relationships with leading labs, founders, and clinicians doing the work, and we structure our work for the way institutional investment committees actually make decisions.
We produce structured intelligence that give allocators a clear, defensible view of where frontier science is heading and where the capital opportunity actually sits. Our research is built from direct relationships with leading labs, founders, and clinicians doing the work, and we structure our work for the way institutional investment committees actually make decisions.
CMD Intelligence is a boutique advisory founded to connect frontier health and biotech research with institutional capital in the Gulf and emerging markets. We combine deep scientific and research credibility with direct relationships across sovereign and institutional capital, and operate at the intersection of science, capital, and policy.
01
Translating frontier biomedical and biotech research into investable propositions .
02
A priority sector where scientific momentum and intuitional capital interest are both accelerating.
03
Deep engagement with Gulf sovereign wealth, family office, and institutional allocators.
04
Understanding the regulatory, strategic, and geopolitical context shaping where frontier science capital flows.
